This 1 Number May Completely Change Your Opinion About Moderna
(NASDAQ: MRNA) stock soared during the pandemic as investors bet on the company's coronavirus vaccine candidate. Since then, the biotech launched a vaccine, followed by updated boosters, and generated billions of dollars in earnings. But the stock-price performance has stumbled in the post-pandemic world, and investors are worried about Moderna's reliance on its only product.
The company may not be a one-product company for long, though. It may not even be a two-product company for long. The company has big plans for the next several years and has set out a roadmap to reach its goals.
Moderna offered investors more details about its projects and prospects this week during its annual R Day. If you're worried about Moderna, one number may completely change your mind.
Source Fool.com
Moderna Inc. Aktie
Deutliches Buy-Überwiegen bei Moderna Inc. im Vergleich zu Sell-Einschätzungen.
Das Kursziel von 129 € für Moderna Inc. bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 64.77 €.
